Henry Schein, Inc. (NASDAQ:HSIC) Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 156,557 shares of the company’s stock after buying an additional 8,015 shares during the period. Everett Harris & Co. CA’s holdings in Henry Schein were worth $10,834,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. ING Groep NV purchased a new position in Henry Schein in the third quarter valued at about $63,226,000. Holocene Advisors LP acquired a new position in Henry Schein during the 3rd quarter worth approximately $58,319,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Henry Schein in the 3rd quarter worth approximately $43,740,000. Southpoint Capital Advisors LP grew its position in Henry Schein by 30.0% in the third quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Henry Schein by 365.6% during the third quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after purchasing an additional 558,689 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $80.00 on Friday. The stock’s fifty day simple moving average is $73.41 and its 200-day simple moving average is $71.43. The company has a market capitalization of $9.97 billion, a price-to-earnings ratio of 32.92, a P/E/G ratio of 2.20 and a beta of 0.89. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.32 EPS. On average, sell-side analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HSIC shares. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. Mizuho assumed coverage on Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target for the company. Evercore ISI lifted their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Barrington Research increased their target price on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein currently has an average rating of “Moderate Buy” and a consensus price target of $80.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.